Current Report Filing (8-k)
December 09 2021 - 4:41PM
Edgar (US Regulatory)
0001616543
false
0001616543
2021-12-08
2021-12-08
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
December 8, 2021
SENSEONICS
HOLDINGS, INC.
|
(Exact Name of Registrant as Specified in its Charter)
|
Delaware
|
|
001-37717
|
|
47-1210911
|
(State or Other
Jurisdiction of Incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer
Identification No.)
|
20451 Seneca Meadows Parkway
Germantown, MD 20876-7005
|
(Address of Principal Executive Office) (Zip Code)
|
Registrant's telephone number, including
area code: (301) 515-7260
Not Applicable
Former name or former address, if changed
since last report
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(see General Instruction A.2 below):
¨ Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
Common Stock, $0.001 par value
|
SENS
|
NYSE American
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 5.02 Departure of Directors or Certain Officers; Election of
Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Appointment of Sharon Larkin to Board of Directors
On December 8, 2021, the board of directors (the “Board”)
of Senseonics Holdings, Inc. (the “Company”) appointed Sharon Larkin to serve as a director of the Company, which appointment
became effective immediately. Ms. Larkin will serve as a Class I director whose term will expire at the 2023 annual meeting
of stockholders.
There is no arrangement or understanding between Ms. Larkin and any
other person pursuant to which she was selected as a director of the Company, and there is no family relationship between Ms. Larkin and
any of the Company’s other directors or executive officers. The Company is not aware of any transaction Ms. Larkin requiring disclosure
under Item 404(a) of Regulation S-K. More information about Ms. Larkin is set forth below:
Sharon Larkin, age 58, is a former senior executive
of Assertio Therapeutics, Inc., having retired in 2020 as senior vice president, Human Resources and Administration. Ms. Larkin joined
Assertio Therapeutics, Inc., in 2017 after retiring from Abbott as divisional vice president, Human Resources, Medical Devices Group,
where she provided global human resources leadership for Abbott’s five medical device operating businesses, including Abbott Diabetes
Care, Abbott Vascular, Abbott Medical Optics, Abbott Animal Health and Abbott Electrophysiology. Ms. Larkin joined Abbott in 1992 and
also held positions of increased responsibility in Abbott’s Nutrition, HealthSystems and Corporate operations. Prior to joining
Abbott, Ms. Larkin worked for the Federal Reserve Bank of Atlanta, Jacksonville Branch, where she provided leadership for the branch’s
U.S. Treasury securities services and human resources operations. Ms. Larkin received a B.S. in industrial management from the Georgia
Institute of Technology.
In connection with her appointment to the Board, Ms. Larkin was
appointed as a member of the Board’s Compensation Committee.
On December 8, 2021, Ms. Larkin was granted a restricted stock unit
for 72,115 shares of the Company’s common stock, which will vest in three equal annual installments, subject to Ms. Larkin’s
continuous service through each such vesting date. In addition, Ms. Larkin will be eligible for an annual retainer of $40,000 for her
service as a director and $6,500 for her service as a member of the Compensation Committee, pursuant to the Company’s non-employee
director compensation policy.
Ms. Larkin is expected to enter into the Company’s standard
form of indemnification agreement with the Company.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
SENSEONICS HOLDINGS, INC.
|
Date: December 9, 2021
|
|
|
By:
|
/s/ Nick Tressler
|
|
Name:
|
Nick Tressler
|
|
Title:
|
Chief Financial Officer
|
Senseonics (AMEX:SENS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Senseonics (AMEX:SENS)
Historical Stock Chart
From Apr 2023 to Apr 2024